IgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m 2 May Still Benefit from RAS Inhibition

Abstract

Introduction. There has been controversy about renin-angiotensin system (RAS) inhibition in IgAN patients with advanced (stage 4) chronic kidney disease (CKD). Therefore, we investigated the effect of RAS blockade in these patients. Methods. Renal specimens of 50 IgAN patients who underwent renal biopsy during stage 4 CKD between 2010 and 2020, were stained using immunohistochemistry to detect the expression of RAS receptors (AT1R, AT2R, MasR, and MrgD). The primary endpoint was a composite of end-stage renal disease (ESRD) and death. Main baseline information and the administration of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) were collected. Results. During a median follow-up time of 25.5 months, 21 (42.0%) patients reached ESRD and none died. Six patients had a baseline eGFR of 15-20 ml/min/1.73m², and reached ESRD with a median renal survival time of 7.0 (range 6.0-23.0) months. Among patients with a baseline eGFR of 20-30 ml/min/1.73m², the percentage of patients using ACEI/ARB in progressive group was much lower than that in stable group (33.3% vs. 62.1%, $P = 0.045$ ), together with a shorter renal survival time in progressive group (26.0 vs. 30.5 months, $P = 0.033$ ). Macroproteinuria ( $24 h - UP \geq 2.5 g$ ) was also associated with a shorter renal survival time, as well as a significant decline in eGFR of stable group (24.4 vs. 26.4 ml/min/1.73 m², $P = 0.026$ ). Lower eGFR [hazards ratio (HR), 0.829, 95% confidence interval (CI), 0.724-0.950; $P = 0.007$ ] and use of ACEI/ARB (HR, 0.356, 95% CI, 0.133-0.953; $P = 0.040$ ) were predictive of time to ESRD in this stage. No differences were found in the expression of AT1R, AT2R, MasR, and MrgD of renal tissues at the time of biopsy between stable and progressive groups. Conclusion. Contingent on monitoring serum creatinine and potassium levels, IgAN with macroproteinuria and a GFR of 20-30 ml/min/1.73m² may still benefits from intrarenal RAS inhibition.

1. Introduction

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and still remains a leading cause of end-stage renal disease (ESRD) [1]. A big challenge for clinicians is its heterogeneous risk of progressive kidney function decline, with up to 50% of affected patients progressing to ESRD in their lifetime [2]. Most commonly, IgAN is asymptomatic at the early stage and when diagnosed, some patients have already suffered different degrees of renal injury. Unlike the majority of glomerular diseases, treatment of IgAN is focused on nonimmunosuppressive-based strategies including lifestyle modification, blood pressure control, and optimal inhibition of renin-angiotensin system (RAS) [3].

It is generally accepted that local overactivation of RAS in kidneys plays a necessary role in pathogenesis of IgAN. Both angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB), collectively called RAS inhibitors (RASi), are now widely used in nearly all kinds of glomerulonephritis because of the renoprotective effect. Many physicians hesitate to use RAS-blocking mediations in patients with advanced (stage 4) chronic kidney disease (CKD), given the concern about the reducing effects of ACEI/ARB on glomerular perfusion and potassium excretion. Consequently, the renal outcome and the risk-benefit profile of RAS inhibitors in this population remain poorly defined [4].

Our team has previously studied the role of conventional therapy in patients with advanced diabetic nephropathy (DN) [5]. Based on this thought, to investigate if ACEI/ARB could continue to delay the onset of ESRD in the late stage of IgAN, we therefore conducted this study to detect the expression of four RAS receptors and the effects of ACEI/ARB in IgAN patients with stage 4 CKD.

2. Methods

2.1. Study Design and Participants

This was a retrospective study. We enrolled patients diagnosed of IgAN who underwent a renal biopsy at China-Japan Friendship Hospital from January 1, 2010 to December 31, 2020. The renal biopsy was operated by clinicians with many years of relevant experience in our department. Inclusion criteria were as follows: (1) biopsy-proven IgAN patients with stage 4 CKD at the time of biopsy; (2) age from 18 to 75 years. The main exclusion criteria were: patients (1) with secondary IgA deposits including purpuric nephritis, lupus nephritis, or coexistence with other glomerular diseases; (2) those without follow-up data (Figure 1).

Figure 1

Flowchart of study participants. IgAN: IgA nephropathy, eGFR: estimated glomerular filtration rate, CKD: chronic kidney disease.

This study was approved by the ethics committee of the China-Japan Friendship Hospital (2021-113-K71). As this was a retrospective observational study of deidentified data, patient informed consent was not required. All the procedures that included human participants adhered to the Declaration of Helsinki.

2.2. Parameters and Definitions

The following clinical parameters were collected from the electronic medical system: gender, age, mean arterial pressure (MAP), 24 h urinary protein excretion (24 h-UP), urinary red blood cell count (URBC,/HPF, the most before renal biopsy), serum creatinine (SCr), hemoglobin (Hb), total cholesterol (TC), triglyceride (TG), parathyroid hormone (PTH), and uric acid (UA). We calculated estimated glomerular filtration rate (eGFR) using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [6]. Postbiopsy use of RAS blockade or immunosuppressive (IS) therapies were also retrospectively reviewed. Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg and (or) diastolic blood pressure (DBP) ≥90 mmHg.

2.3. Endpoints and Follow-Up

The primary endpoint was a composite of ESRD and death. ESRD was defined as the initiation of maintenance dialysis or renal transplantation. A three-year follow-up was conducted. The progressive group was defined as those with the occurrence of the endpoint events, and the stable group was patients whose renal function was still maintained in stage 4 CKD.

2.4. Renal Biopsy and Immunohistochemistry (IHC) of RAS Receptors

The antibody used in this study was the anti-angiotensin II type 1 receptor (AT1R) antibody (Abcam, ab124505, 1: 500), anti-angiotensin II type 2 receptor (AT2R) antibody (Abcam, ab254561, 1: 400), anti-Mas receptor (MasR) antibody (Abcam, ab66030, 1: 100), and anti-Mas associated G protein coupled receptor D (MrgD) antibody (Invitrogen, PA5-100957, 1: 400). Paraffin-embedded tissues were sectioned at 3 μm thickness. After dewaxing and hydration treatment, heat-mediated antigen retrieval was performed for all the receptors. The sections for staining AT1R and MasR were treated with citrate buffer while those for staining AT2R and MrgD were treated with ethylene diamine tetraacetic acid (EDTA) buffer [Gene Tech (Shanghai) Co., Ltd, GT100411, 1: 50]. After immunostaining, all sections were counterstained with hematoxylin. Immunohistochemical images were obtained using a Moticam 2506 instrument (Motic, Fujian, China) from sections observed microscopically at ×400 magnification (Nikon, Tokyo, Japan). The images were acquired using an integrated digital camera system (Nikon). Immunoreactivity was semiquantitatively evaluated in a blinded manner. Image Pro-plus (IPP) computer image analysis software (Media Cybernetics, Bethesda, MD, USA) was used to analyze the pixel density of the stained areas, and to quantify protein levels.

2.5. Statistical Analysis

Continuous data were regarded as nonparametric and were presented as median and interquartile range (IQR). Differences were analyzed using the Mann–Whitney $U$ nonparametric test. Categorical variables were reported as percentages and analyzed using the chi-square or Fisher’s exact test. Univariate and multivariate Cox proportional hazard model was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for variables related to the composite outcome. Statistical analysis was performed using SPSS software (version 24.0; IBM Corp, Armonk, NY) and GraphPad Prism 8.0. Two-sided $P$ values <0.05 were considered to indicate statistical significance.

3. Results

3.1. Baseline and Pathological Characteristics

We totally enrolled 50 IgAN patients with stage 4 CKD at the time of biopsy aged 18-75 years, who underwent renal biopsy in the China-Japan Friendship Hospital from 2010 to 2020. The clinical characteristics of the patients are presented in Table 1. The median age of all patients was 40.5 (IQR 29.8-49.3) years, and 24 (48.0%) patients were male. The median eGFR was 25.8 (23.1-26.8) ml/min/1.73m². The median 24 h-UP was 2.7 (1.5-4.3) g. By the end of the follow-up, 21 (42.0%) of the 50 patients progressed to ESRD. None died or developed hyperkalemia ( $serum potassium \geq 6.0 mmol / l$ ) or acute kidney injury (AKI) requiring hospitalization [5]. At baseline, there was no significant difference in main biochemical parameters such as Hb (119.0 vs. 107.0 g/l, $P = 0.075$ ), eGFR (25.7 vs. 24.3 ml/min/1.73m², $P = 0.072$ ), and 24 h-UP (2.0 vs. 3.0 g/d, $P = 0.149$ ) between the progressive group and stable group. Similarly, there was also no difference in the main parameters between the two groups if stratified by use of RASi (Supplementary Table 1). Although there was a significant difference in the time of follow-up, 18 (62.1%) patients in the stable group received RAS blockade therapy after biopsy while the percentage in progressive group was 33.3% ( $P = 0.045$ ). This difference could also be found between using RASi group and without RASi group (Supplementary Table 1). There were 15 (of 50) patients using RASi prior to biopsy, but they all use the drugs very irregularly or just for a short time (no more than 3 weeks).

Table 1

Clinical baseline of IgAN patients with stage 4 CKD.

Clinical parameters	Total ( $n = 50$ )	Stable ( $n = 29$ )	Progressive ( $n = 21$ )	$P$ value
Clinical findings
Age (y)	40.5 (29.8-49.3)	43.0 (29.5-58.0)	37.0 (29.5-44.5)	0.132
Gender, M (%)	24 (48.0)	16 (55.2)	8 (38.1)	0.233
SBP (mmHg)	135.0 (122.0-147.0)	130.0 (121.0-139.5)	141.0 (125.5-151.0)	0.205
DBP (mmHg)	85.0 (77.8-96.5)	80.0 (76.0-90.0)	93.0 (79.0-100.0)	0.061
MAP (mmHg)	100.2 (95.2-113.0)	98.7 (90.5-103.0)	107.33 (97.2-116.0)	0.080
Hypertension, $n$ (%)	30 (60.0)	17 (58.6)	13 (61.9)	0.815
Use of RASi, $n$ (%)	25 (50.0)	18 (61.2)	7 (33.3)	0.045
Use of IS, $n$ (%)	25 (50.0)	17 (58.6)	8 (38.1)	0.152
Laboratory findings
Hb (g/l)	115.5 (103.8-125.3)	119.0 (110.0-126.5)	107.0 (97.0-120.0)	0.075
eGFR (ml/min/1.73m²)	25.8 (23.1-26.8)	25.7 (24.1-27.6)	24.3 (19.7-26.6)	0.072
UA (μmol/l)	478.5 (440.5-536.8)	477.0 (450.0-525.5)	480.0 (410.0-574.5)	0.891
iPTH (pg/ml)	76.8 (50.5-136.8)	68.0 (47.5-99.5)	91.4 (58.2-192.3)	0.071
TC (mmol/l)	5.0 (4.1-6.2)	4.8 (4.0-6.1)	6.0 (4.2-6.7)	0.135
TG (mmol/l)	1.8 (1.6-2.4)	1.8 (1.5-2.9)	2.0 (1.6-2.3)	0.340
24 h-UP (g)	2.7 (1.5-4.4)	2.0 (1.5-4.5)	3.0 (1.8-4.4)	0.149
URBC (/HPF)	11.2 (4.7-36.9)	11.5 (4.3-31.1)	10.2 (4.6-42.4)	0.992
Follow-up time (months)	25.5 (12.0-36.0)	36.0 (22.0-36.0)	15.0 (7.5-28.5)	<0.001

IgAN, IgA nephropathy; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RASi, renin-angiotensin system inhibitor; IS, immunosuppressive agents; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; UA, uric acid; PTH, parathyroid hormone; TC, total cholesterol; TG, triglyceride; 24 h-UP, 24 h urinary protein excretion; URBC, urinary red blood cells.

3.2. Follow-Up and Renal Outcomes

Fifteen (71.4%) patients in the progressive group had a baseline eGFR of 20-30 ml/min/1.73m², and the other six (28.6%) patients had baseline eGFR values of 15-20 ml/min/1.73m². All 29 patients in the stable group had a baseline eGFR of 20-30 ml/min/1.73m². By the end of follow-up, a significant difference in renal survival time was observed between the progressive and stable groups [24.0 (range 6.0-36.0) vs. 30.5 months (8.0-36.0), $P = 0.003$ ], and none of the patients in the stable group progressed to the endpoint. The median renal survival time of patients in the progressive group with a baseline eGFR of 15-20 ml/min/1.73 m² was 7.0 (6.0-23.0) months, much shorter than that in patients with a baseline eGFR of 20-30 ml/min/1.73 m² ( $P < 0.001$ , Figure 2(a)). Furthermore, the median renal survival time among all patients whose baseline eGFR was 20-30 ml/min/1.73 m² was significantly different between the progressive and stable groups (26.0 vs. 30.5 months, $P = 0.033$ ). Yet, no decline in renal function was observed in the stable group at the end of follow-up compared to the baseline level (24.4 vs. 25.7 ml/min/1.73 m², $P = 0.414$ ). These results suggest that a lower baseline eGFR indicated worse renal survival in IgAN patients with stage 4 CKD. We then analyzed ACEI/ARB use in the two groups. One third of the patients in the progressive group used an ACEI/ARB, which was much lower than the percentage in the stable group (62.1%, $P = 0.045$ ). With a baseline eGFR of 20-30 ml/min/1.73 m², those not receiving ACEI/ARB therapy shared a median renal survival time of 30.0 months ( $P = 0.006$ ). The results were shown in Figure 2.

Figure 2

Subgroup analysis suggesting that the mean renal survival time varied according to the baseline eGFR and 24 h-UP. The mean renal survival time was significantly longer in those with a baseline eGFR of 20-30 ml/min/1.73 m² and $24 h - UP < 2.5 g$ ((a, b), $P < 0.001$ and $P = 0.042$ , respectively). In patients with a baseline eGFR of 20-30 ml/min/1.73 m², RAS blockade resulted in a prolonged renal survival time ((c), $P = 0.006$ ).

(b)

(c)

We separated the patients into two subgroups according to the baseline 24 h-UP level, with a threshold value of 2.5 g/d. The same was applied to the stable group. The mean survival times of patients with $24 h - UP < 2.5 g$ and ≥ 2.5 g in the progressive group were 30.0 and 24.5 months, respectively ( $P = 0.043$ ). A notable decrease in eGFR was detected in the stable group by the end of follow-up (24.4 vs. 26.4 ml/min/1.73 m², $P = 0.026$ ) in those whose $24 h - UP \geq 2.5 g$ , while the median eGFR at the end of follow-up and at baseline were 24.0 and 25.0 ml/min/1.73 m² among those with a $24 h - UP < 2.5 g$ in the stable group ( $P = 0.381$ ). The result indicates that more urinary protein excretion was associated with a shorter renal survival time. Multivariate Cox analysis suggested that the baseline eGFR level ( $P = 0.007$ ), use of RASi ( $P = 0.040$ ) were independent risk factors for renal endpoints in IgAN patients with stage 4 CKD (Table 2).

Table 2

Univariate and multivariate Cox regression analysis of IgAN patients with stage 4 CKD.

Variables	Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	$P$	HR (95% CI)	$P$
Age (y)	0.962 (0.925-1.001)	0.055
Gender	1.496 (0.619-3.615)	0.371
SBP	0.998 (0.969-1.029)	0.912
DBP	1.023 (0.976-1.073)	0.343
MAP	1.018 (0.989-1.046)	0.223
Hb	0.977 (0.949-1.006)	0.122
eGFR	0.801 (0.696-0.921)	0.002	0.829 (0.724-0.950)	0.007
UA	0.998 (0.992-1.004)	0.554
iPTH	1.001 (0.999-1.002)	0.526
TC	1.178 (0.902-1.539)	0.230
TG	1.089 (0.771-1.537)	0.629
URBC	0.999 (0.994-1.003)	0.569
24 h-UP	1.157 (0.962-1.391)	0.121	1.108 (0.922-1.331)	0.275
Hypertension	1.017 (0.421-2.460)	0.970
RASi	0.259 (0.103-0.653)	0.004	0.356 (0.133-0.953)	0.040
IS	0.608 (0.252-1.466)	0.268

SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RASi, renin-angiotensin system inhibitor; IS, immunosuppressive agents; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; UA, uric acid; PTH, parathyroid hormone; TC, total cholesterol; TG, triglyceride; 24 h-UP, 24 h urinary protein excretion; URBC, urinary red blood cells.

3.3. Angiotensin Receptors Expression and RAS-Blocking Mediation

Overactivation of the RAS plays an important role in the pathogenesis of IgAN, and our IHC results support this statement. IHC staining showed that the expression of the angiotensin receptors (AT1R, AT2R, MasR, and MrgD) increased significantly in IgAN renal tissues of stage 4 CKD, whether progressive or stable group, compared to those with stage 1 CKD (mild mesangial proliferative glomerulonephritis) at the time of renal biopsy. Patients in progressive group exhibited a higher expression of AT1R and AT2R and lower expression of MasR, while the expression of MrgD receptor was similar in the two groups. However, all the differences of four receptors between the progressive and stable groups were not significant. The expression of the four receptors is shown in Figures 3 and 4.

Figure 3

Immunohistochemical staining suggests increased expression of AT1R and AT2R ((a, c) ×400) and decreased expression of MasR ((b), ×400) of IgAN patients with stage 4 CKD in the stable and progressive groups, while MrgD receptor expression was similar ((d), ×400).

(b)

(c)

(d)

Figure 4

IHC showed a significant increased expression of the four receptors in IgAN patients with stage 4 CKD compared to the control group (IgAN patients with stage 1 CKD who had normal renal function with mild mesangial proliferative glomerulonephritis on biopsy). No significant difference was observed in the expression levels of AT1R (a), AT2R (b), MasR (c), and MrgD receptors (d) in renal biopsy specimens between stable and progressive groups. AOD, average optical density. $* P < 0.05$ ; $* * P < 0.01$ ; $* * * P < 0.001$ ; ns, no significance.

(b)

(c)

(d)

4. Discussion

IgAN is now still the most common primary glomerulonephritis worldwide. Patients may suffer various degrees of renal insufficiency at the time of diagnosis. With a severe renal injury, patients with stage 4 CKD often have already lost the opportunities of renal biopsy for a definite diagnosis, leading to a limited clinical and pathological data. RAS inhibition is now one of the main therapies for IgAN but remains controversial in those with severe renal injury. To our knowledge, this is the specific study demonstrating the effects and prognostic relevance of ACEI/ARB in advanced (stage 4 CKD) IgAN patients. Since current information indicates that most of patients with stage 4 CKD are not offered such renal protective treatment, our results may have important implications for the development of new therapeutic guidelines.

The role of renal RAS overactivation has been long highlighted in the onset of IgAN. Our previous studies also supported the statement [7]. AT1, AT2, Mas, and MrgD receptors are the main four receptors for angiotensin. AT1R usually mediates vasoconstriction, cell proliferation, and renal fibrosis, which is the main target of ARB drugs. The molecular and cellular actions of angiotensin II in cardiovascular and renal diseases are almost exclusively mediated via the AT1R [8]. AT1R inhibition reduces blood pressure and has anti-inflammatory and antiproliferative effects, while an increasing number of publications emphasize the role of AT2R in the so-called protective arm of RAS [9]. Besides, MasR is also regarded as a kind of protective receptor as angiotensin (1-7), which functions as a vasodilator and antiproliferative agent, is the physiologic ligand of the MasR. MrgD is a member of Mas-related G protein coupled receptor family. There are only a few studies about the MrgD receptor and its endogenous ligand alamandine, but the structural resemblance of the ligands angiotensin (1-7) and alamandine as well as of the receptors Mas and MrgD suggests a possible role of MrgD in blood pressure regulation and hypertension [10]. So far, there are very few publications demonstrating the correlation between MrgD and IgAN. Our immunohistochemical results indicated that AT1R and AT2R expression were significantly increased in advanced IgAN, whereas a decreased expression of MasR and similar expression of MrgD compared to those with stage 1 CKD at the time of biopsy. However, no differences of the expression of the four receptors were found between progressive and stable groups. This may provide some evidence about MrgD in IgAN.

With a median follow-up time of our patients which was 25.5 months, multivariate Cox regression analysis suggested the baseline eGFR was a strong prognostic factor for IgAN patients with stage 4 CKD. Patients with baseline eGFR <20 ml/min/1.73 m² might rapidly progress to renal end points according to our results. Although there was a difference of renal survival between patients with $24 h - UP \geq 2.5 g / d$ and < 2.5 g/d, 24 h-UP is not observed as a risk factor for IgAN patients with stage 4 CKD according to our study. This may be due to the relatively limited sample size and the more severe renal injuries of patients in our study at the time of biopsy. In recent years, the prognostic significance of hematuria in IgAN has drawn people’s attention [11, 12], while there was no significant correlation between hematuria and prognosis in this study, probably because our focus was on patients with badly impaired renal function.

For IgAN patients with macroproteinuria and a GFR of <30 ml/min/1.73 m², despite glucocorticoids and some novel immunosuppressants [13, 14], the 2021 KDIGO guideline no longer recommends immunosuppression in these patients as it may do more harm than good [3]. So far, RAS blockade is still the first-line treatment of IgAN and even almost other kinds of glomerulonephritis. Increased risk of hyperkalemia or elevating serum creatinine discourages the use of RAS-blocking mediation in those with advanced CKD. However, there are some stage 4 CKD patients benefiting from ACEI/ARB in trials, including the AIPRI [15], ESBARI [4], STOP-IgAN [16], and TESTING [17] trials. Angiotensin receptors, especially AT1R, were still upregulated in these patients, supporting the use of RAS inhibition. Consequently, a total of 25 patients received RAS blockade after biopsy, 7 (33.3%) in progressive group and 18 (62.1%) in stable group, respectively. All of these patients shared the baseline eGFR of 20-30 ml/min/1.73m². Our results suggested the use of an ACEI/ARB was predictive of the time to ESRD for IgAN patients with macroproteinuria and a GFR of 20-30 ml/min/1.73m². Therefore, AECI/ARB may still bring a renal benefit for advanced (stage 4 CKD) IgAN in a 3-year follow-up.

Nevertheless, there are several limitations of our study. First, due to the severe renal injury and the high risk of postbiopsy complications, such as bleeding, patients with stage 4 CKD were seldom biopsied for a definite diagnosis. Therefore, our study may mean something for the precious data of these patients. Yet, our findings still need to be confirmed in a multicenter study with a larger sample size. Moreover, this is a retrospective study and presents methodologic limitations that must be taken into account, so causality was difficult to infer. Proportional hazards regression incorporating time-varying covariates may create time-varying confounding. Besides, we included cases during ten years, so it was a difficulty for us to find the data of all the patients prior to biopsy.

5. Conclusion

In summary, ACEI/ARB therapy may still be considered in IgAN patients with macroproteinuria and a GFR of 20-30 ml/min/1.73m², contingent on monitoring serum creatinine and potassium levels.

Footnotes

Data Availability

All data are available and displayed in our article.

Conflicts of Interest

All authors declare no financial competing interests.

Acknowledgments

This work was supported by the National Key Clinical Specialty Capacity Building Project (grant number 2019-542). We thank the participants of the study. We also thank the Department of Nephrology, China-Japan Friends Hospital, for providing the technical assistance.

Supplementary Materials

References

Xie

Zhao

Zhou

Jia

Liu

Hou

F. F.

Intensity of macrophage infiltration in glomeruli predicts response to immunosuppressive therapy in patients with IgA nephropathy

Journal of the American Society of Nephrology 2021 32

9162427

12 3187 3196

10.1681/ASN.2021060815

34670812

Lafayette

R. A.

Canetta

P. A.

Rovin

B. H.

Appel

G. B.

Novak

Nath

K. A.

Sethi

Tumlin

J. A.

Mehta

Hogan

Erickson

Julian

B. A.

Leung

Enders

F. T.

Brown

Knoppova

Hall

Fervenza

F. C.

A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction

Journal of the American Society of Nephrology 2017 28

9162427

4 1306 1313

10.1681/ASN.2016060640

2-s2.0-85020350091

27821627

Rovin

B. H.

Adler

S. G.

Barratt

Bridoux

Burdge

K. A.

Chan

T. M.

Cook

H. T.

Fervenza

F. C.

Gibson

K. L.

Glassock

R. J.

Jayne

D. R. W.

Jha

Liew

Liu

Z.-H.

Mejía-Vilet

J. M.

Nester

C. M.

Radhakrishnan

Rave

E. M.

Reich

H. N.

Ronco

Sanders

J.-S. F.

Sethi

Suzuki

Tang

S. C. W.

Tesar

Vivarelli

Wetzels

J. F. M.

Floege

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

Kidney International 2021 100

9162427

4 S1 S276

10.1016/j.kint.2021.05.021

34556256

Hou

F. F.

Zhang

G. H.

Xie

Chen

P. Y.

Zhang

W. R.

Jiang

J. P.

Liang

Wang

G. B.

Liu

Z. R.

Geng

R. W.

Efficacy and safety of benazepril for advanced chronic renal insufficiency

The New England Journal of Medicine 2006 354

9162427

2 131 140

10.1056/NEJMoa053107

2-s2.0-30444452987

16407508

Jiang

Yang

Fang

Zou

Gao

Zhuo

The treatment effectiveness evaluation for slowing the progression of diabetic nephropathy during stage 4 chronic kidney disease

Diabetes Therapy 2021 12

9162427

1 301 312

10.1007/s13300-020-00970-3

Inker

L. A.

Schmid

C. H.

Tighiouart

Eckfeldt

J. H.

Feldman

H. I.

Greene

Kusek

J. W.

Manzi

van Lente

Zhang

Y. L.

Coresh

Levey

A. S.

CKD-EPI Investigators

Estimating glomerular filtration rate from serum creatinine and cystatin C

The New England Journal of Medicine 2012 367

9162427

1 20 29

10.1056/NEJMoa1114248

2-s2.0-84863524855

22762315

Zhang

Jiang

S. M.

Y. P.

Dai

P. L.

Wang

Y. N.

Zou

G. M.

Gao

H. M.

Yang

W. G.

Expression of the intrarenal angiotensin receptor and the role of renin-angiotensin system inhibitors in IgA nephropathy

Molecular and Cellular Biochemistry 2019 453

9162427

1-2 103 110

10.1007/s11010-018-3435-4

2-s2.0-85052714063

30159797

Kim

Iwao

Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases

Pharmacological Reviews 2000 52

9162427

1 11 34

10699153

Schleifenbaum

Alamandine and its receptor MrgD pair up to join the protective arm of the renin-angiotensin system

Frontiers in Medicine 2019 6

9162427

107

10.3389/fmed.2019.00107

31245374

10.

Young

Waitches

Birchmeier

Fasano

Wigler

Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains

Cell 1986 45

9162427

5 711 719

10.1016/0092-8674(86)90785-3

2-s2.0-0022536710

11.

G. Z.

Guo

Dong

J. F.

Shi

S. F.

Liu

L. J.

Wang

J. W.

Sui

G. L.

Zhou

X. J.

Xing

H. X.

J. C.

Zhang

Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study

American Journal of Kidney Diseases 2020 76

9162427

1 90 99

10.1053/j.ajkd.2019.11.008

32197881

12.

Sevillano

A. M.

Gutiérrez

Yuste

Cavero

Mérida

Rodríguez

García

Morales

Fernández

Martínez

M. A.

Moreno

J. A.

Praga

Remission of hematuria improves renal survival in IgA nephropathy

Journal of the American Society of Nephrology 2017 28

9162427

10 3089 3099

10.1681/ASN.2017010108

2-s2.0-85030460087

28592423

13.

Fellström

B. C.

Barratt

Cook

Coppo

Feehally

de Fijter

J. W.

Floege

Hetzel

Jardine

A. G.

Locatelli

Maes

B. D.

Mercer

Ortiz

Praga

Sørensen

S. S.

Tesar

del Vecchio

NEFIGAN Trial Investigators

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Lancet 2017 389

9162427

10084 2117 2127

10.1016/S0140-6736(17)30550-0

2-s2.0-85016574686

28363480

14.

Liu

L. J.

Yang

Y. Z.

Shi

S. F.

Bao

Y. F.

Yang

Zhu

S. N.

Sui

G. L.

Chen

Y. Q.

J. C.

Zhang

Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial

American Journal of Kidney Diseases 2019 74

9162427

1 15 22

10.1053/j.ajkd.2019.01.026

2-s2.0-85063296388

15.

Maschio

Alberti

Janin

Locatelli

Mann

J. F. E.

Motolese

Ponticelli

Ritz

Zucchelli

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency

The New England Journal of Medicine 1996 334

9162427

15 939 945

10.1056/NEJM199604113341502

2-s2.0-15844368318

16.

Rauen

Eitner

Fitzner

Sommerer

Zeier

Otte

Panzer

Peters

Benck

Mertens

P. R.

Kuhlmann

Witzke

Gross

Vielhauer

Mann

J. F.

Hilgers

R. D.

Floege

STOP-IgAN Investigators

Intensive supportive care plus immunosuppression in IgA nephropathy

The New England Journal of Medicine 2015 373

9162427

23 2225 2236

10.1056/NEJMoa1415463

2-s2.0-84948798394

26630142

17.

Zhang

Wong

M. G.

Jardine

M. J.

Hladunewich

Jha

Monaghan

Zhao

Barbour

Reich

Cattran

Glassock

Levin

Wheeler

Woodward

Billot

Chan

T. M.

Liu

Z. H.

Johnson

D. W.

Cass

Feehally

Floege

Remuzzi

Agarwal

Wang

H. Y.

Perkovic

for the TESTING Study Group

Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy

JAMA 2017 318

9162427

5 432 442

10.1001/jama.2017.9362

2-s2.0-85027500963

28763548